Animal funds

Elanco Animal Health Incorporated (NYSE: ELAN) Receives an Average “Moderate Buy” Recommendation from Analysts

Shares of Elanco Animal Health Incorporated (NYSE: ELAN – Get a rating) received an average rating of “moderate buy” from the six research firms that currently cover the company, reports MarketBeat Ratings. Three analysts rated the stock with a hold recommendation and three gave the company a buy recommendation. The 12-month average price target among analysts who updated their stock coverage in the last year is $32.20.

A number of equity analysts have recently commented on ELAN shares. Goldman Sachs Group cut its price target on Elanco Animal Health shares from $37.00 to $32.00 and set a “buy” rating for the company in a Thursday, May 19 research report. Morgan Stanley cut its price target on shares of Elanco Animal Health to $37.00 and set an “overweight” rating for the company in a Tuesday, May 17 research report. Stifel Nicolaus cut his price target on Elanco Animal Health shares from $30.00 to $22.00 and set a “holding” rating for the company in a Friday, June 24 research report. Finally, Piper Sandler launched a hedge on Elanco Animal Health shares in a research report on Monday. They set a “neutral” rating for the company.

In other Elanco Animal Health news, Director John P. Bilbrey bought 10,000 shares of the company in a trade on Wednesday, May 11. The shares were acquired at an average price of $22.03 per share, with a total value of $220,300.00. Following the transaction, the administrator now owns 34,222 shares of the company, valued at $753,910.66. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, available at this link. Insiders hold 6.40% of the shares of the company.

A number of institutional investors have recently changed their positions in ELAN. 1832 Asset Management LP increased its stake in shares of Elanco Animal Health by 11.3% in the fourth quarter. 1832 Asset Management LP now owns 1,484,650 shares of the company worth $42,964,000 after purchasing an additional 150,462 shares in the last quarter. Resonant Capital Advisors LLC increased its stake in Elanco Animal Health by 4.5% in Q1. Resonant Capital Advisors LLC now owns 14,294 shares of the company worth $373,000 after buying 614 additional shares in the last quarter. The New York State Common Retirement Fund increased its position in shares of Elanco Animal Health by 11.0% in the fourth quarter. The New York State Common Retirement Fund now owns 760,061 shares of the company valued at $21,571,000 after acquiring an additional 75,573 shares in the last quarter. Allianz Asset Management GmbH increased its stake in shares of Elanco Animal Health by 20.9% in the fourth quarter. Allianz Asset Management GmbH now owns 1,101,427 shares of the company worth $31,258,000 after acquiring an additional 190,114 shares during the period. Finally, First Hawaiian Bank increased its position in Elanco Animal Health shares by 16.0% during the first quarter. First Hawaiian Bank now owns 36,800 shares of the company worth $960,000 after buying 5,067 additional shares in the last quarter.

NYSE ELAN was down $0.23 during Monday trading hours, hitting $20.22. 2,213,935 shares of the company were traded, against an average volume of 4,707,229. Elanco Animal Health has a 1-year minimum of $19.34 and a 1-year maximum of $37.49. The company’s 50-day simple moving average is $22.32 and its 200-day simple moving average is $25.10. The company has a quick ratio of 1.41, a current ratio of 2.44 and a debt ratio of 0.80. The stock has a market capitalization of $9.59 billion, a P/E ratio of -27.32, a P/E/G ratio of 1.00 and a beta of 0.81.

Elanco Animal Health (NYSE: ELAN – Get a rating) last released its quarterly earnings data on Monday, May 9. The company reported earnings per share (EPS) of $0.36 for the quarter, beating analyst consensus estimates of $0.35 by $0.01. Elanco Animal Health recorded a negative net margin of 7.65% and a positive return on equity of 6.61%. The company posted revenue of $1.23 billion in the quarter, versus a consensus estimate of $1.22 billion. In the same quarter last year, the company posted earnings per share of $0.37. The company’s quarterly revenue fell 1.4% from the same quarter last year. As a group, sell-side analysts expect Elanco Animal Health to post earnings per share of 1.17 for the current year.

About Elanco Animal Health (Get a rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets pet and farm animal products. It offers pet disease prevention products, such as parasiticides and vaccines that protect animals against worms, fleas and ticks under the Seresto, Advantage, Advantix and Advocate brand names; companion animal health therapies for pain, osteoarthritis, ear infections, cardiovascular and dermatological indications in dogs and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides and other products for poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides and other products used in ruminant and swine production under the Rumensin and Baytril brands.

See also

Analyst Recommendations for Elanco Animal Health (NYSE: ELAN)

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Elanco Animal Health right now?

Before you consider Elanco Animal Health, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Elanco Animal Health didn’t make the list.

Although Elanco Animal Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here